Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria® in Patients With Atypical Hemolytic Uremic Syndrome
Latest Information Update: 11 Aug 2022
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- Sponsors GENERIUM Pharmaceuticals
- 02 Aug 2022 Status changed from recruiting to completed.
- 15 Feb 2021 New trial record